Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings
ARQT·Reported May 14, 2024·After market close
Arcutis Biotherapeutics, Inc. reported Q1 2024 revenue of $49.6M, beat analyst consensus of $14.7M by $34.8M. Diluted EPS came in at $-0.32, beat the $-0.60 consensus by $0.28.
Revenue
$49.6Mbeat by $34.8M
Consensus: $14.7MDiluted EPS
$-0.32beat by $0.28
Consensus: $-0.60
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Arcutis Biotherapeutics, Inc.'s Q1 2024 earnings report.
Arcutis Biotherapeutics, Inc. (ARQT) reported Q1 2024 earnings on May 14, 2024 after market close.
Arcutis Biotherapeutics, Inc. reported revenue of $49.6M and diluted EPS of $-0.32 for Q1 2024.
Revenue beat the consensus estimate of $14.7M by $34.8M. EPS beat the consensus estimate of $-0.60 by $0.28.
You can read the 10-Q periodic report (0001787306-24-000079) directly on SEC EDGAR. The filing index links above go to sec.gov.